Name of subsidiary Place of incorporation and business Principal activities Effective ownership interest and voting interest 2023 % 2022 % Indirect subsidiaries (continued) Held through Parkway Life Japan4 Pte. Ltd.: (continued) Godo Kaisha Samurai 17 ++ Japan Special purpose entity – Investment in real estate 35.56 35.58 Godo Kaisha Samurai 18 ++ Japan Special purpose entity – Investment in real estate 35.56 35.58 Godo Kaisha Samurai 19 ++ Japan Special purpose entity – Investment in real estate 35.56 35.58 Held through Parkway Life Malaysia Pte. Ltd.: Parkway Life Malaysia Sdn. Bhd. Malaysia Special purpose entity – Investment in real estate 35.56 35.58 Held through Angsana Holdings Pte. Ltd.: Angsana Molecular & Diagnostics Laboratory Pte. Ltd. # Singapore Provision of medical laboratories including biochemistry, chemistry, haematology and molecular blood analysis and testing – 55.00 Angsana Molecular & Diagnostics Laboratory (HK) Limited # Hong Kong Provision of molecular diagnostic assays and services – 55.00 Angsana Molecular & Diagnostics Laboratory Sdn. Bhd. Malaysia Research laboratories and carry on business, including taking blood samples for testing – 55.00 1 PPL and PHL hold 99.99% and 0.01% shares in Parkway HK Holdings Limited respectively. 2 PPL and PHL hold 78.52% and 21.48% shares in Parkway Group Healthcare Pte. Ltd. (“PGH”) respectively. 3 PPL holds more than 99.99% shares in GDPL. The remaining shares are held by Gleneagles International Pte. Ltd.. 4 GDPL and Parkway-Healthcare (Mauritius) Ltd. hold 96.67% and 1.50% shares in GHIPL respectively. 5 GDPL and PGH hold more than 99.99% and less than 0.01% in Parkway Healthcare India Private Limited respectively. 6 MRI and Shanghai Mai Kang Hospital Investment Management Co., Ltd. (“Shanghai Mai Kang”) hold 70% and 30% shares in Shanghai Rui Xin Healthcare Co., Ltd. respectively. 7 MRI and Shanghai Mai Kang hold 70% and 30% shares in Shanghai Rui Hong Clinic Co., Ltd. respectively. 8 MRI and Shanghai Mai Kang hold 70% and 30% shares in Shanghai Xin Rui Healthcare Co., Ltd. respectively. 9 Fortis and Fortis Health Management Limited (“FHML”) hold 74.35% and 25.65% shares in Fortis Hospotel Limited respectively. 10 Fortis and FHML hold 78.40% and 21.60% shares in International Hospital Limited (“IHL”) respectively. 11 Fortis and IHL hold 52% and 48% shares in FHML respectively. 12 Fortis, IHL and FHML hold 48.58%, 38.29% and 13.13% shares in Escorts Heart and Super Speciality Hospital Limited respectively. 13 Agilus Diagnostics Limited (f.k.a. SRL Limited) and Agilus Pathlabs Private Limited (f.k.a. SRL Diagnostics Private Limited) hold 50% shares each in DDRC Agilus Pathlabs Limited (f.k.a. DDRC SRL Diagnostics Limited) respectively. 14 Parkway Investments Pte. Ltd., PTM and Integrated Healthcare Holdings Limited hold 35.25% (2022: 35.25%), 0.27% (2022: 0.29%) and 0.04% (2022: 0.04%) of the units in PLife REIT respectively. 15 During the year, Fortis Healthcare International Pte. Ltd. is dissolved and its direct subsidiary, Mena Healthcare Investment Company Limited becomes a direct subsidiary of Fortis Asia Healthcare Pte. Ltd.. # Audited by other member firms of KPMG International. ## Audited by firms other than member firms of KPMG International. + Audit is not required. ++ Not required to be audited under the laws of country of incorporation. These special purpose entities have been consolidated in the financial statements in accordance with MFRS 10, as the Group primarily bears the risks and enjoys the benefits of the investments held by these special purpose entities. ^ The entity was granted approval by Companies Commission of Malaysia to have a financial year which does not coincide with the Company. Annual Report 2023 245 41. SUBSIDIARIES (continued)
RkJQdWJsaXNoZXIy NDgzMzc=